XOMA — Xoma Royalty Share News
0.000.00%
Last trade - 00:00- $792.01m
- $808.75m
- $52.15m
Xoma Corp Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Brief: XOMA Appoints New Executive Leadership Team
Brief: Xoma Acquires Royalty And Milestone License To Ebopiprant, A Preterm Labor Asset, Being Developed By Organon
ObsEva surges on license sale of preterm labor drug to XOMA Corp
Xoma Corp Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Xoma Reports Third Quarter Financial Results
Xoma Corp Expected To Post A Loss Of 23 Cents A Share: Earnings Preview
Brief: Xoma Reports Q2 Revenue Of $1.0 Million
Xoma Corp Reports Results For The Quarter Ended In March: Earnings Summary
Brief: XOMA Reports First Quarter 2022 Financial Results
Xoma Corp Expected To Post A Loss Of 36 Cents A Share: Earnings Preview
Xoma Corp Reports Results For The Quarter Ended In December: Earnings Summary
Brief: XOMA Reports Full Year 2021 Financial Results And Highlights Recent Operational Events
Xoma Corp Expected To Post Earnings Of $2.27 A Share: Earnings Preview
Brief: Xoma Corp Says CEO Jim Neal To Retire, When His Successor Has Been Appointed
Xoma Corp Reports Results For The Quarter Ended In September: Earnings Summary
Brief: XOMA Earns $35 Mln Milestone Payment As Anti-TGFβ Antibody Enters Phase 3 Clinical Study In Metastatic Pancreatic Cancer
Xoma Corp Expected To Post A Loss Of 20 Cents A Share: Earnings Preview
Brief: Xoma Corp Entered Into Commercial Payment Purchase Agreement With Affitech Research AS